Among inhibitors of TGF-β, LY2157299 has also been considered as an anti-cancer agent (Bueno et al., 2008), and Tranilast has been widely used as an antioxidant (Holmes et al., 2000), antiallergic (Kondo et al., 1992), antiangiogenesis (Isaji et al., 1997), and anti-inflammatory agent (Shiota et al., 2010). Here, TGFB1 is linked to cancer.